Page 97 - Demo

Plasma microRNAs in oesophageal and gastric cancer9550 5 10 15 20 25050100miR-375 ACMonthsPercent survivalHigh expressionLow expression (a) (b) Figure 3. (a) Kaplan-Meier analysis of OS in patients with GC in relation to plasma miR-200c-3p. N=5 in each group; p=0.06. (b) Kaplan-Meier analysis of OS in patients with EAC in relation to plasma miR-375. N=9 in each group; p=0.02.EC and combined AC analysisA significant relation was found between a high miR-375 expression and a better OS (14.9 vs. 10.1 months; HR=0.4 95% CI: 0.1 to 1.1, p=0.02) in patients with EC, while this was not observed for PFS (HR=0.5 95% CI: 0.2-1.3, p=0.1) (Table 3 and Figure 3b). No statistically significant relations were found between miR-200c-3p, miR21-5p or miR-148-3p expression and either OS or PFS (Table 3). A combinatorial analysis of miR-375 combined with miR-21-5p or miR-200c-3p did not result in an increased significant relation to OS (data not shown). Since adenocarcinomas from patients with AC primary from GC and EC origin show similar molecular patterns [39] and for both circulating miR-200c-3p was determined, the analysis was also performed on these groups combined. However, miR-200c-3p was not related to OS or PFS in this group (Table 3).ESCCNo significant relation was found between miR-200c-3p, miR-375, miR-21-5p or miR-148-3p expression and OS or PFS in patients with ESCC (Table 3).miRNA expression at baseline and during chemotherapy in plasma of patients with GC and ECMeasurable baseline and follow-up samples were available of 7 patients with GC and 6 patients with EC (n= 4 AC; n = 2 SCC). miR-200c-3p (n=7), miR-146-5p